Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
At what ANC do you hold weekly Taxol for adjuvant therapy of Her2 positive breast cancer?
Answer from: Medical Oncologist at Academic Institution
it depends a little on risk of bleeding and disease, but in general 100k I dose reduce. Hold at 80k.
Comments
Medical Oncologist at Allegheny General Hospital-Western Pennsylvania Hospital
Would hold if ANC less than 1000 Proceed and sup...
Medical Oncologist at Dana-Farber Cancer Institute
In the APT trial, we required an ANC > 800 to dose...
1409
1410
Sign in or Register to read more
5254
Related Questions
What are your top takeaways in Medical Oncology from SABCS 2024?
Would you offer adjuvant chemotherapy to a premenopausal woman with HR+ HER2 negative IDC, T1cN0, with isolated tumor cells, oncotype RS 20, grade 2, with multifocal LVI?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
Would you omit radiation for an elderly woman with bilateral breast cancers (both early-stage disease and ER+/PR+/HER2 negative) who otherwise meets the criteria for endocrine therapy alone?
Would you discontinue or dose-reduce Tamoxifen in a patient that developed hepatic steatosis?
would you recommend ALND to a postmenopausal female with one positive lymph node and small volume metastasis in other Lymph nodes?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/Her2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Would hold if ANC less than 1000 Proceed and sup...
In the APT trial, we required an ANC > 800 to dose...